Cargando…
HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
BACKGROUND: Interstitial fibrosis and fibrotic scar formation contribute to cardiac remodeling and loss of cardiac function in myocardial infarction (MI) and heart failure. Recent studies showed that histone deacetylase (HDAC) inhibitors retard fibrosis formation in acute MI settings. However, it is...
Autores principales: | Nural-Guvener, Hikmet F, Zakharova, Luidmila, Nimlos, James, Popovic, Snjezana, Mastroeni, Diego, Gaballa, Mohamed A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094898/ https://www.ncbi.nlm.nih.gov/pubmed/25024745 http://dx.doi.org/10.1186/1755-1536-7-10 |
Ejemplares similares
-
Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure
por: Nural-Guvener, Hikmet, et al.
Publicado: (2015) -
Chronic Heart Failure Is Associated With Transforming Growth Factor Beta‐Dependent Yield and Functional Decline in Atrial Explant‐Derived c‐Kit+ Cells
por: Zakharova, Liudmila, et al.
Publicado: (2013) -
Cardiac Explant-Derived Cells Are Regulated by Notch-Modulated Mesenchymal Transition
por: Zakharova, Liudmila, et al.
Publicado: (2012) -
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
por: Meidhof, Simone, et al.
Publicado: (2015) -
Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6
por: Zhang, Q, et al.
Publicado: (2016)